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Thoracic aortic endovascular repair for mycotic
aneurysms and fistulas
Himanshu J. Patel, MD,a David M. Williams, MD,b Gilbert R. Upchurch, Jr., MD,aNarasimham L. Dasika, MD,b Jonathan L. Eliason, MD,a and G. Michael Deeb, MD,a Ann Arbor, MichInfected thoracic aortic aneurysms are a rare pathologic
entity.1-11 Presentation can occur with constitutional
symptoms (fevers, failure to thrive, weight loss), chest
pain, or with symptoms attributable to adjacent organ
development. The latter group often includes back pain
from erosion into vertebrae, hemoptysis from aorto-
bronchial fistulae, and hematemesis or odynophagia
from aortoesophageal fistulae. The diagnosis is made
based on clinical presentation, characteristic radio-
graphic findings, and microbiologic data. The underly-
ing aortic pathology in mycotic aneurysm is typically a
saccular configuration. In contrast, fistulae between the
thoracic aorta and adjacent organ systems can present with
underlying fusiform, dissecting, or saccular aneurysms.
The mortality of medically treated infected thoracic
aortic pathology (ITAP) exceeds 60%.1While open surgical
repair has been considered the gold standard, reported
mortality from this approach can exceed 12% in the largest
series to date.1-4 Classic surgical principles in the treatment
of open repair include wide debridement of infected tissue
and extra-anatomic bypass. Recent work has suggested that
in situ grafting may be appropriate, and some authors have
recognized the potential for use of rifampin-soaked grafts
as a means for reducing risk for reinfection.1
Recognizing the potential role of endovascular therapy
(TEVAR), we and others have suggested that TEVAR
represents a minimally invasive option in treating often
moribund patients and have reported early mortality rates
as low as 0%.5-8,11 This review updates our previous work
and summarizes the current efforts reported in the litera-
ture.
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This retrospective study was approved by the Institu-
tional Review Board (IRB) of the University of Michigan
Hospitals. Informed consent requirements were waived for
this study. From 1993 to 2010, 27 patients (median age 72
years, 66.7% male) have undergone TEVAR for infected
thoracic aortic pathology at the University of Michigan
Hospitals. Of this group, 26 were considered high risk for
open surgery, while the remaining patient refused open
surgery and was offered TEVAR as an alternative. In six
patients (22.2%), the procedure was performed in the set-
ting of an infected Dacron graft. The underlying pathology
contributing to the presentation included saccular aneu-
rysm (23), aortic dissection (2), and fusiform aneurysm (1),
while the remaining patient developed a fistula between an
otherwise normal aortic contour and a gastric conduit used
after transhiatal esophagectomy. Of the entire study co-
hort, 14 patients presented with a mycotic aneurysm. Six-
teen patients from the entire cohort had associated fistulous
connections, including aortobronchial (12), aortoesopha-
geal (3), and aortocutaneous (1) fistulae.
Statistical methods to analyze the data included univar-
iate (2 or independent sample t test) andmultivariate (Cox
proportional hazards analysis with forward selection pro-
cess). Survival was analyzed by Kaplan-Meier analysis and
vital status verified using the Social Security Death Index.
Follow-up for the primary outcome of all cause mortality
was 100% complete (mean 26.4  33.6 months).
RESULTS
Comorbidities in this group were prevalent and in-
cluded hypertension (18), chronic obstructive pulmonary
disease (7), coronary artery disease (8), peripheral vascular
disease (6), and a history of tobacco use (19). One pre-
sented with end-stage renal failure needing dialysis, and the
mean creatinine for the cohort was 1.4  1.5 mg/dL.
Importantly, a history of immunosuppression was identi-
fied in four and malignancy in seven. Prior aortic repair in
this cohort consisted of abdominal aortic aneurysmectomy
(4), prior descending aortic repair (3), and aortic valve
replacement with ascending aneurysmectomy (1).
Early results. Technical success was achieved in all but
one patient. That patient presented with a graft infection
following two prior thoracotomies and for coarctation re-
pair and then repair of a large postcoarctation pseudoaneu-
rysm. He had an inadequate proximal landing zone to
extend therapy to exclude the sac and underwent unevent-
ful graft explantation and extra-anatomic ascending to su-
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the next day. Concomitant procedures included hybrid
arch debranching with (1) and without coronary artery
bypass grafting (1), and visceral/renal debranching (2).
In-hospital mortality was seen in three patients (11.5%).
The causes of mortality included refractory hypoxemia
following massive hemoptysis prior to TEVAR in one,
multidrug resistant pneumonia in another, and finally tra-
cheoesophageal fistula in one who presented with an aor-
toesophageal fistula.Majormorbidity included the need for
hemodialysis in two patients (7.4%), both of whom had
impaired renal function at baseline (creatinine 2.0 mg/
dL). The incidence of postoperative pneumonia was five
(18.5%). Neither stroke nor spinal cord ischemia was iden-
tified following TEVAR.
The antibiotic regimen in this group varied but in-
cluded the institution of antibiotics for at least 48 hours
prior to surgery in 18 (66.7%). Postoperative antibiotic
regimens included prolonged courses (greater than 3
weeks) in all but one patient. This patient presented with
hemoptysis; the aortobronchial fistula was initially sus-
pected secondary to pulmonary parenchymal erosion rather
than infection. She died 4 months later, following identifi-
cation of an endoleak and gas bubbles in the aneurysm sac
consistent with infection. At the age of 95 years, she was
not considered a suitable candidate for open graft explan-
tation and extra-anatomic bypass.
Late results. In this debilitated population, the overall
crude mortality rate was 65% (n  14), with four deaths
attributable to aortic reinfection. The Kaplan-Meier sur-
vival curve is shown in Fig 1 and demonstrates a 3-year
survival of 57.8%. There were no univariate correlates with
late mortality.
Endoleak was seen in five patients (18.5%). Proximal
landing zone endoleaks were identified in one patient oc-
Fig 1. Kaplan-Meier survival analysis demonstrates the poor
prognosis associated with infected thoracic aortic pathology
(ITAP). In this cohort, 3-year survival was 58.4%.curring intraoperatively from inadequate proximal landingzone length and described above. The remaining patients
had indeterminate endoleaks. One underwent TEVAR for
an aortobronchial fistula in the setting of previous chronic
dissection. He continues to be followed, but has a stable
indeterminate endoleak (type 2 or 3) with a decreasing sac
size 2 years following TEVAR. An indeterminate type was
identified in another who eventually expired 4 months after
TEVAR of unknown cause. The third patient (95-year-old)
developed an indeterminate endoleak (type 1 or 2) with gas
bubbles in the aneurysm sac 4 months after TEVAR as
described above. The last patient is currently being fol-
lowed and has a stable sac size.
At 2 years, Kaplan-Meier freedom from reinfection was
Fig 2. Freedom from aortic reinfection is demonstrated for the
entire cohort in (a). The 2-year freedom from reinfection is 81.2%
in the entire cohort. However, when stratified by treatment in
native vs prosthetic graft, there is a significant difference in freedom
from reinfection at 2 years (native aorta 92.9% vs prosthetic graft
60%; P  .028, b). By multivariate analysis, this factor was identi-
fied as independently predictive of late reinfection (Cox HR 
8.05, P  .063).81.2% (Fig 2, A). Univariate variables correlating with
, myc
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fistulous connection (vs mycotic aneurysm, P  .06),
TEVAR extending into the arch (P  .047) or for pros-
thetic graft infection (vs native graft, P  .004). When
these variables were entered into Cox multivariate analysis,
only TEVAR for a prosthetic graft infection was indepen-
dently associated with an increased risk for reinfection
(HR  8.05, P  .063). This was confirmed following
Kaplan-Meier analysis, where TEVAR into the native aorta
portended a decreased risk for reinfection (Fig 2, B, log
rank P  .028).
DISCUSSION
The infected thoracic aorta remains among the most
formidable of clinical challenges. While optimal medical
therapy is associated with a dismal prognosis, any operative
intervention is associated with high rates of morbidity and
mortality.1-11 The advent of thoracic endovascular repair as
a less invasive therapy has the potential to resolve this
judgmental paradox. Previous authors have reported their
experiences with early and late results of TEVAR.5-8,11-13
However, these outcomes have been mixed, with some
authors suggesting a low rate of reinfection. A summary of
recent work is listed in the Table. Heterogeneous study
groups described in these analyses may explain the discrep-
ant results listed. For example, aortobronchial fistulae can
occur secondary to erosion of the aneurysm into pulmonary
parenchymal bronchioles rather than to a pneumonia in-
fecting an aneurysm or prosthetic graft. The results of
TEVAR in this particular example are likely to be different.
Different duration of antibiotic therapy may also explain
these differences in outcomes.5,7,8 Our preference is to
recommend antibiotics for at least 6 weeks, and preferen-
tially for life in this setting where wide debridement of
infected tissues is not performed and endografts are main-
tained in an infected field. An analogy is drawn to the
treatment of endocarditis where extensive infection is
treated with prolonged courses of antibiotics and the
source of infection is removed.
Our study was conducted to focus on outcomes follow-
ing TEVAR for ITAP and represents one of the largest
cohorts treated by an endovascular approach. The results
suggest that this therapy can be performed safely with
relatively low rates of early morbidity in a high-risk group.
In this series, early mortality was 11.5%. There was no
Table. Summary of series treating infectious thoracic aort
First author Year of study Pre
Bockler12 2004 Aortobronchia
Gonzalez-Fajardo7 2005 Aortoesophag
Pirrelli13 2006 Aortobronchia
Ting6 2006 Mycotic aneur
Wheatley8 2007 Aortobronchia
Farber11 2009 Aortobronchia
Patel5 2009 Mixed fistulaeparaplegia or stroke in this cohort, and the rate of tempo-rary dialysis was 7.4%. Late results remain poor, but the risk
of late mortality is often related to the underlying comor-
bidities frequently present in this high-risk population. Risk
of reinfection is significant, and our work is the first to
suggest that the results are poorer in the setting of TEVAR
for infected graft vs native aorta. While this finding is novel,
the basis for this is supported by the reported (but low) rate
of treatment success with antibiotic therapy alone. Antibi-
otic therapy may be able to sterilize native tissue but not
infected graft, and wide debridement may be mandatory in
that setting. Again, the parallel is drawn toward endocardi-
tis where sterilization of valve infection without surgery is
possible.
In summary, thoracic endovascular repair is considered
a suitable but palliative therapeutic option in patients pre-
senting with infected thoracic aortic pathology. Late mor-
tality in this high-risk group is often secondary to underly-
ing pathology rather than to reinfection. Late reinfection
may be more frequent when TEVAR is performed for
prosthetic graft infection rather than native aortic infection.
However, the low incidence of this disease makes a direct
comparison to the gold standard of open repair difficult,
and thus its role as either a definitive or bridge therapy
remains elusive.
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